IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025
Summary
IceCure reported its financial and operational results for the nine months ended September 30, 2025. The company highlighted FDA marketing authorization for its ProSense cryoablation system in low-risk breast cancer and said demand is building in the U.S. and internationally. It also outlined upcoming commercial rollouts, reimbursement opportunities, and additional regulatory plans in Switzerland and Japan. Financially, revenue declined year over year, while operating expenses fell and the company ended the period with about $10.0 million in cash. IceCure also noted that its July rights offering and ATM sales strengthened liquidity to support commercialization.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected